Results 71 to 80 of about 281,052 (341)

The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance [PDF]

open access: yes, 2019
Ovarian cancer is the most lethal of all gynecologic malignancies and the eighth leading cause of cancer-related deaths among women worldwide. The main reasons for this poor prognosis are late diagnosis; when the disease is already in an advanced stage ...
Berx, Geert   +3 more
core   +2 more sources

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

open access: yesMolecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza   +3 more
wiley   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

open access: yes, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Enhancement of paclitaxel transport and cytotoxicity by 7,3’,4’-trimethoxyflavone, a P-glycoprotein inhibitor

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2007
Purpose.: Paclitaxel has problems with respect to bioavailability and resistance. The aim of this study was to select a P-glycoprotein (Pgp)- inhibitory flavonoid to enhance paclitaxel bioavailability in the Caco-2 cell monolayer. Methods.
Ju-Mi Jeong, Cheol-Hee Choi
doaj   +1 more source

Injectable diblock copolypeptide hydrogel provides platform to maintain high local concentrations of taxol and local tumor control [PDF]

open access: yes, 2019
Introduction Surgical resection and systemic chemotherapy with temozolomide remain the mainstay for treatment of glioblastoma. However, many patients are not candidates for surgical resection given inaccessible tumor location or poor health status ...
Bernstein, Alexander   +9 more
core  

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

open access: yes, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo   +7 more
core   +2 more sources

Bioengineering facets of the tumor microenvironment in 3D tumor models: insights into cellular, biophysical and biochemical interactions

open access: yesFEBS Open Bio, EarlyView.
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik   +3 more
wiley   +1 more source

Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis

open access: yesBMC Research Notes, 2012
Background The chemotherapeutic agent paclitaxel arrests cell division by binding to the hetero-dimeric protein tubulin. Subtle differences in tubulin sequences, across eukaryotes and among β-tubulin isotypes, can have profound impact on paclitaxel ...
Das Lalita   +2 more
doaj   +1 more source

Repurposing metformin for cancer treatment: current clinical studies. [PDF]

open access: yes, 2016
In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic ...
Altman, Jessica K   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy